Livongo Health (NASDAQ:LVGO) stands out as one of the stocks that have benefited tremendously from the COVID-19 pandemic this year. The company’s digital health platform helps individuals manage chronic conditions like diabetes and hypertension. With the pandemic increasing the need for remote health monitoring and personalized healthcare, Livongo was in the right place at the right time.

Some investors were also in the right place at the right time by buying Livongo shares at the company’s initial public offering last year. They’ve won big from the rise of the healthcare stock in 2020. Here’s how much you would have now if you’d invested $10,000 in Livongo Health’s IPO.

Smiling woman holding a smartphone with images of dollar signs over it.

Image source: Getty Images.

Counting the cash

If you’d been able to buy at Livongo’s IPO price of $28, an initial investment of $10,000 would have given you 357 shares. If we assume you didn’t buy partial shares, you would’ve had a few bucks left over to buy a cup of coffee or two.

Of course, not everyone is able to get in on an IPO. Most investors have to wait until a stock begins trading to buy it. This would have made a big difference with Livongo’s IPO. Its shares opened at $40.51 on July 25, 2019 — nearly 45% above its IPO price. An initial investment of $10,000 at the market open of Livongo’s first trading day would have gotten you 246 shares. You would’ve had over $34 left over; enough to buy a decent meal.

It’s possible (and perhaps probable) that you would’ve regretted your investment for several months. Livongo closed out 2019 down more than 10% from its IPO price and down 34% from its first day of trading, but the stock went on a tear in 2020.

LVGO Chart

LVGO data by YCharts

If you’d held onto your Livongo

Gilead Sciences (NASDAQ:GILD) has been in the news lately, with President Trump receiving doses of Gilead’s experimental antiviral drug Veklury (remdesivir) earlier this month to help treat his coronavirus infection. It’s already been an up-and-down year for Gilead — in March, the stock hit a 52-week high of $85.97 on hopes that Veklury, originally tested to fight Ebola, would be the big answer to ending the coronavirus pandemic.

The stock slowly came down to earth, however, hurt by a May report in the New England Journal of Medicine that said Veklury only shortened the time of hospitalization by four days in COVID-19 patients, compared to a placebo.

Earlier in October, the stock was trading at about $62 a share, which — while a long way from $85 — is more than three times what it went for after its initial public offering (IPO) in January of 1992.

Businessman holding onto a climbing arrow that shows compounding interest.

Image source: Getty Images.

Patient investors would have done quite well

On Jan. 22, 1992, the day of its IPO, Gilead traded for $20.16 per share. So, if you had $1,000 to spend on the stock back then, you would have been able to purchase 49 shares of Gilead. Over time and several stock splits, that would have grown to 1,568 shares today, which would make your original investment, not counting any reinvested dividends, worth $99,724.80 as of Monday’s close. That’s a compound annual growth rate (CAGR) of 17.9% and an overall return of 9,995%.

More recent Gilead investors haven’t been as fortunate. As recently as the summer of 2015, when the company’s drugs dominated the hepatitis C market, the stock was trading at $118 per share. Since then, facing growing competition in that market, the company’s revenues have fallen each year, from $32 billion in 2015 to $22 billion last year. Halfway